Table 3. Results of the univariate analysis for the overall survival and disease-free survival.
| Baseline and clinical features | OS | DFS | ||||||
|---|---|---|---|---|---|---|---|---|
| Patients | HR | 95% CI | p-value | HR | 95% CI | p value | ||
| Pathological stage | I/II | 9 | 1.000 | 1.000 | ||||
| III/IV | 8 | 0.950 | 0.273–3.306 | 0.935 | 1.465 | 0.365–5.887 | 0.590 | |
| Maximum diamater of tumor | <Mean (55.4 mm) | 10 | 1.000 | 1.000 | ||||
| >Mean (55.4 mm) | 7 | 1.185 | 0.350–4.010 | 0.924 | 2.106 | 0.500–8.873 | 0.310 | |
| Pathological N factor | N0/N1 | 14 | 1.000 | 1.000 | ||||
| N2 | 3 | 1.406 | 0.290–6.818 | 0.672 | 4.960 | 1.096–22.434 | 0.038 | |
| Sarcomatous elements | spindle cell only | 7 | 1.000 | 1.000 | ||||
| others | 10 | 0.931 | 0.281–3.087 | 0.907 | 0.743 | 0.185–2.984 | 0.676 | |
| Epithelial component | adenocarcinoma | 7 | 1.000 | 1.000 | ||||
| others | 10 | 0.332 | 0.082–1..347 | 0.123 | 0.178 | 0.035–0.895 | 0.036 | |
| Lymphatic permiation factor | – | 11 | 1.000 | 1.000 | ||||
| + | 6 | 0.951 | 0.276–3.270 | 0.936 | 1.240 | 0.293–5.246 | 0.770 | |
| Vascular invasion factor | – | 5 | 1.000 | 1.000 | ||||
| + | 12 | 0.813 | 0.235–2.808 | 0.743 | 0.948 | 0.225–4.001 | 0.942 | |
| Adjuvant chemotherapy | – | 10 | 1.000 | 1.000 | ||||
| + | 7 | 2.525 | 0.652–9.778 | 0.180 | 2.563 | 0.514–12.768 | 0.251 | |
| TDT (n = 16) | <Median (48.9 days) | 11 | 1.000 | 1.000 | ||||
| >Median (48.9 days) | 5 | 1.849 | 0.544–6.277 | 0.325 | 1.043 | 0.258–4.211 | 0.953 | |
| DFI | <12 months | 8 | 1.000 | |||||
| >12 months | 9 | 0.095 | 0.018–0.491 | 0.005 | ||||
DFI: disease-free interval; DFS: disease-free survival; HR: hazard ratio; OS: overall survival; TDT: tumor doubling time; 95% CI: 95% confidence interval